Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jeffrey G. Supko, Ph.D.

Co-Author

This page shows the publications co-authored by Jeffrey Supko and Jeffrey Clark.
Connection Strength

0.814
  1. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors. Clin Cancer Res. 2003 Nov 01; 9(14):5178-86.
    View in: PubMed
    Score: 0.278
  2. Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors. Clin Cancer Res. 2009 Jan 01; 15(1):374-81.
    View in: PubMed
    Score: 0.099
  3. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2006 Jul; 58(1):107-16.
    View in: PubMed
    Score: 0.080
  4. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors. Clin Cancer Res. 2004 Apr 01; 10(7):2222-30.
    View in: PubMed
    Score: 0.071
  5. Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer. Clin Colorectal Cancer. 2004 Feb; 3(4):225-34.
    View in: PubMed
    Score: 0.071
  6. A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors. Cancer. 2003 Jan 01; 97(1):148-54.
    View in: PubMed
    Score: 0.066
  7. Phase 1 study of N(1),N(11)-diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2013 Dec; 72(6):1305-14.
    View in: PubMed
    Score: 0.035
  8. Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol. 2007 Oct; 60(5):661-70.
    View in: PubMed
    Score: 0.022
  9. A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors. Cancer. 2006 Dec 01; 107(11):2688-97.
    View in: PubMed
    Score: 0.021
  10. Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors. Cancer. 2006 Nov 15; 107(10):2482-9.
    View in: PubMed
    Score: 0.021
  11. A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies. Invest New Drugs. 2004 Apr; 22(2):139-50.
    View in: PubMed
    Score: 0.018
  12. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol. 2002 Sep 15; 20(18):3772-84.
    View in: PubMed
    Score: 0.016
  13. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors. Clin Cancer Res. 2002 Mar; 8(3):691-7.
    View in: PubMed
    Score: 0.015
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.